Skip to main content
SpringerLink
Log in
Book cover

HIV and the Brain pp 213–232Cite as

Co-Occurrence of HIV, Hepatitis C, and Substance Use Disorders: Effects on Brain Functioning

  • Chapter
  • First Online:

  • 893 Accesses

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

Most notably, substance use disorders (SUDs) and Hepatitis C (HCV) are the two conditions that commonly co-occur with HIV and share in common a number of neuropathological and neurocognitive sequelae. In this chapter, we present and evaluate research that examines neurocognitive functioning among HIV-infected persons who are also infected with HCV and/or have a SUD. As we highlight throughout, the presence of an SUD and/or HCV in concert with HIV infection may increase the vulnerability to neurocognitive dysfunction. In the process, we also devote some attention to unique challenges in the study of these vulnerable populations and briefly touch upon some treatmentrelated issues.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. UNAIDS. Report on the Global AIDS Epidemic 2006. Joint United Nations Programme on HIV/AIDS.

    Google Scholar 

  2. Stimson GV, Choopanya K. Global perspectives on drug injecting. In: Stimson GV, Des Jarlais DC, Ball A, editors. Drug Injecting and HIV Infection: Global Dimensions and Local responses (Social Aspects of AIDS). London: UCL Press, 1998: 1–21.

    Google Scholar 

  3. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36(5 Suppl 1):S93–S98.

    PubMed  Google Scholar 

  4. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74(4):212–220.

    CAS  Google Scholar 

  5. Hagan H, Des J. HIV and HCV infection among injecting drug users. Mt Sinai J Med 2000; 67(5–6):423–428.

    PubMed  CAS  Google Scholar 

  6. Strathdee SA, Patterson TL. Behavioral interventions for HIV-positive and HCV-positive drug users. AIDS Behav 2006; 10(2):115–130.

    PubMed  Google Scholar 

  7. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34(6):831–837.

    PubMed  Google Scholar 

  8. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32(3):492–497.

    PubMed  CAS  Google Scholar 

  9. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24(3):211–217.

    PubMed  CAS  Google Scholar 

  10. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des J, Flom PL et al. Non-injection drug use and Hepatitis C Virus: a systematic review. Drug Alcohol Depend 2007; 89(1):1–12.

    PubMed  Google Scholar 

  11. Gyarmathy VA, Neaigus A, Miller M, Friedman SR, Des J. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr 2002; 30(4):448–456.

    PubMed  Google Scholar 

  12. Howe CJ, Fuller CM, Ompad DC, Galea S, Koblin B, Thomas D et al. Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York city. Drug Alcohol Depend 2005; 79(3):389–395.

    PubMed  Google Scholar 

  13. Gonzales R, Marinelli-Casey P, Shoptaw S, Ang A, Rawson RA. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. J Subst Abuse Treat 2006; 31(2):195–202.

    PubMed  Google Scholar 

  14. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21(8):983–991.

    PubMed  Google Scholar 

  15. Macdonald N, Dougan S, McGarrigle CA, Baster K, Rice BD, Evans BG et al. Recent trends in diagnoses of HIV and other sexually transmitted infections in England and Wales among men who have sex with men. Sex Transm Infect 2004; 80(6):492–497.

    PubMed  CAS  Google Scholar 

  16. Dodds JP, Mercey DE, Parry JV, Johnson AM. Increasing risk behaviour and high levels of undiagnosed HIV infection in a community sample of homosexual men. Sex Transm Infect 2004; 80(3):236–240.

    PubMed  CAS  Google Scholar 

  17. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292(2):224–236.

    PubMed  CAS  Google Scholar 

  18. Clifford DB, Yang Y, Evans S. Neurologic consequences of hepatitis C and human immunodeficiency virus coinfection. J Neurovirol 2005; 11(Suppl 3):67–71.

    PubMed  Google Scholar 

  19. Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS 2005; 19(Suppl 3):S53–S63.

    PubMed  Google Scholar 

  20. Gonzalez R, Jacobus J, Martin EM. Investigating neurocognitive features of hepatitis C virus infection in drug users: potential challenges and lessons learned from the HIV literature. Clin Infect Dis 2005; 41(Suppl 1):S45–S49.

    PubMed  Google Scholar 

  21. Perry W, Carlson MD, Barakat F, Hilsabeck RC, Schiehser DM, Mathews C et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS 2005; 19(Suppl 3):S79–S84.

    PubMed  Google Scholar 

  22. Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci 2008; 53(2):307–321.

    PubMed  Google Scholar 

  23. Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol 2006; 47(3):330–342.

    PubMed  CAS  Google Scholar 

  24. Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 2002; 31(Suppl 2):S62–S69.

    PubMed  CAS  Google Scholar 

  25. Brinkman WJ, Hall DM, Suo JL, Weber RJ. Centrally-mediated opioid-induced immunosuppression. Elucidation of sympathetic nervous system involvement. Adv Exp Med Biol 1998; 437:43–49.

    PubMed  CAS  Google Scholar 

  26. Vallejo R, Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11(5):354–365.

    PubMed  Google Scholar 

  27. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol 1998; 83(1–2):77–87.

    PubMed  CAS  Google Scholar 

  28. Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol 1998; 83(1–2):63–69.

    PubMed  CAS  Google Scholar 

  29. Li Y, Wang X, Tian S, Guo CJ, Douglas SD, Ho WZ. Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 2002; 185(1):118–122.

    PubMed  CAS  Google Scholar 

  30. Peterson PK, Gekker G, Hu S, Lokensgard J, Portoghese PS, Chao CC. Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor. Neuropharmacology 1999; 38(2):273–278.

    PubMed  CAS  Google Scholar 

  31. Schweitzer C, Keller F, Schmitt MP, Jaeck D, Adloff M, Schmitt C et al. Morphine stimulates HIV replication in primary cultures of human Kupffer cells. Res Virol 1991; 142(2–3):189–195.

    PubMed  CAS  Google Scholar 

  32. Quang-Cantagrel ND, Wallace MS, Ashar N, Mathews C. Long-term methadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection. Eur J Pain 2001; 5(4):415–420.

    PubMed  CAS  Google Scholar 

  33. Wang X, Tan N, Douglas SD, Zhang T, Wang YJ, Ho WZ. Morphine inhibits CD8+ T cell-mediated, noncytolytic, anti-HIV activity in latently infected immune cells. J Leukoc Biol 2005; 78(3):772–776.

    PubMed  CAS  Google Scholar 

  34. Stefano GB. Substance abuse and HIV-gp120: are opiates protective? Arch Immunol Ther Exp 1999; 47(2):99–106.

    CAS  Google Scholar 

  35. Everall IP. Interaction between HIV and intravenous heroin abuse? J Neuroimmunol 2004; 147(1–2):13–15.

    PubMed  CAS  Google Scholar 

  36. Pellegrino T, Bayer BM. In vivo effects of cocaine on immune cell function. J Neuroimmunol 1998; 83(1–2):139–147.

    PubMed  CAS  Google Scholar 

  37. Tyor WR, Middaugh LD. Do alcohol and cocaine abuse alter the course of HIV-associated dementia complex? J Leukoc Biol 1999; 65(4):475–481.

    PubMed  CAS  Google Scholar 

  38. In SW, Son EW, Rhee DK, Pyo S. Methamphetamine administration produces immunomodulation in mice. J Toxicol Environ Health A 2005; 68(23–24):2133–2145.

    PubMed  CAS  Google Scholar 

  39. Gavrilin MA, Mathes LE, Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol 2002; 8(3):240–249.

    PubMed  CAS  Google Scholar 

  40. Yu Q, Zhang D, Walston M, Zhang J, Liu Y, Watson RR. Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int Immunopharmacol 2002; 2(7):951–962.

    PubMed  CAS  Google Scholar 

  41. Klonoff DC, Andrews BT, Obana WG. Stroke associated with cocaine use. Arch Neurol 1989; 46(9):989–993.

    PubMed  CAS  Google Scholar 

  42. Rothrock JF, Rubenstein R, Lyden PD. Ischemic stroke associated with methamphetamine inhalation. Neurology 1988; 38(4):589–592.

    PubMed  CAS  Google Scholar 

  43. Strickland TL, Miller BL, Kowell A, Stein R. Neurobiology of cocaine-induced organic brain impairment: contributions from functional neuroimaging. Neuropsychol Rev 1998; 8(1):1–9.

    PubMed  CAS  Google Scholar 

  44. Wang AM, Suojanen JN, Colucci VM, Rumbaugh CL, Hollenberg NK. Cocaine- and methamphetamine-induced acute cerebral vasospasm: an angiographic study in rabbits. Am J Neuroradiol 1990; 11(6):1141–1146.

    PubMed  CAS  Google Scholar 

  45. Fiala M, Gan XH, Zhang L, House SD, Newton T, Graves MC et al. Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine’s connection to AIDS dementia and vasculitis? Adv Exp Med Biol 1998; 437:199–205.

    PubMed  CAS  Google Scholar 

  46. Fiala M, Eshleman AJ, Cashman J, Lin J, Lossinsky AS, Suarez V et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol 2005; 11(3):281–291.

    PubMed  CAS  Google Scholar 

  47. Zhang L, Looney D, Taub D, Chang SL, Way D, Witte MH et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 1998; 4(6):619–626.

    PubMed  CAS  Google Scholar 

  48. Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, Booze RM. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 2006; 27(2):217–228.

    PubMed  CAS  Google Scholar 

  49. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 2003; 984(1–2):133–142.

    PubMed  CAS  Google Scholar 

  50. Langford D, Grigorian A, Hurford R, Adame A, Crews L, Masliah E. The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. J Neurovirol 2004; 10(6):327–337.

    PubMed  CAS  Google Scholar 

  51. Maragos WF, Young KL, Turchan JT, Guseva M, Pauly JR, Nath A et al. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 2002; 83(4):955–963.

    PubMed  CAS  Google Scholar 

  52. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 2000; 14(3):222–227.

    PubMed  CAS  Google Scholar 

  53. Theodore S, Cass WA, Maragos WF. Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 2006; 137(3):925–935.

    PubMed  CAS  Google Scholar 

  54. Dingle GA, Oei TP. Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Psychol Bull 1997; 122(1):56–71.

    PubMed  CAS  Google Scholar 

  55. Acheampong E, Mukhtar M, Parveen Z, Ngoubilly N, Ahmad N, Patel C et al. Ethanol strongly potentiates apoptosis induced by HIV-1 proteins in primary human brain microvascular endothelial cells. Virology 2002; 304(2):222–234.

    PubMed  CAS  Google Scholar 

  56. Toborek M, Lee YW, Flora G, Pu H, Andras IE, Wylegala E et al. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 2005; 25(1):181–199.

    PubMed  Google Scholar 

  57. Meyerhoff DJ. Effects of alcohol and HIV infection on the central nervous system. Alcohol Res Health 2001; 25(4):288–298.

    PubMed  CAS  Google Scholar 

  58. Wang Y, Watson RR. Is alcohol consumption a cofactor in the development of acquired immunodeficiency syndrome? Alcohol 1995; 12(2):105–109.

    PubMed  Google Scholar 

  59. Cabral GA, Staab A. Effects on the immune system. Handb Exp Pharmacol 2005; 168:385–423.

    PubMed  CAS  Google Scholar 

  60. Massi P, Vaccani A, Parolaro D. Cannabinoids, immune system and cytokine network. Curr Pharm Des 2006; 12(24):3135–3146.

    PubMed  CAS  Google Scholar 

  61. Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci 2005; 77(14):1711–1722.

    PubMed  CAS  Google Scholar 

  62. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003; 139(4):258–266.

    PubMed  CAS  Google Scholar 

  63. Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 2002; 42(Suppl 11):82S–89S.

    PubMed  CAS  Google Scholar 

  64. Bell JE. An update on the neuropathology of HIV in the HAART era. Histopathology 2004; 45(6):549–559.

    PubMed  CAS  Google Scholar 

  65. Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res 2005; 8(1–2):51–61.

    PubMed  CAS  Google Scholar 

  66. Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003; 13(2):195–210.

    PubMed  CAS  Google Scholar 

  67. Bell JE, Donaldson YK, Lowrie S, McKenzie CA, Elton RA, Chiswick A et al. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS 1996; 10(5):493–499.

    PubMed  CAS  Google Scholar 

  68. Davies J, Everall IP, Weich S, McLaughlin J, Scaravilli F, Lantos PL. HIV-associated brain pathology in the United Kingdom: an epidemiological study. AIDS 1997; 11(9):1145–1150.

    PubMed  CAS  Google Scholar 

  69. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Does drug abuse alter microglial phenotype and cell turnover in the context of advancing HIV infection? Neuropathol Appl Neurobiol 2005; 31(3):325–338.

    PubMed  CAS  Google Scholar 

  70. Bell JE, Arango JC, Robertson R, Brettle RP, Leen C, Simmonds P. HIV and drug misuse in the Edinburgh cohort. J Acquir Immune Defic Syndr 2002; 31(Suppl 2):S35–S42.

    PubMed  CAS  Google Scholar 

  71. Arango JC, Simmonds P, Brettle RP, Bell JE. Does drug abuse influence the microglial response in AIDS and HIV encephalitis? AIDS 2004; 18(Suppl 1):S69–S74.

    PubMed  Google Scholar 

  72. Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K. Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. Arch Pathol Lab Med 2002; 126(2):182–190.

    PubMed  Google Scholar 

  73. Langford D, Adame A, Grigorian A, Grant I, McCutchan JA, Ellis RJ et al. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 2003; 34(5):467–474.

    PubMed  CAS  Google Scholar 

  74. Chana G, Everall IP, Crews L, Langford D, Adame A, Grant I et al. Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 2006; 67(8):1486–1489.

    PubMed  CAS  Google Scholar 

  75. Pfefferbaum A, Adalsteinsson E, Sullivan EV. Cortical NAA deficits in HIV infection without dementia: influence of alcoholism comorbidity. Neuropsychopharmacology 2005; 30(7):1392–1399.

    PubMed  CAS  Google Scholar 

  76. Taylor MJ, Alhassoon OM, Schweinsburg BC, Videen JS, Grant I. MR spectroscopy in HIV and stimulant dependence HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 2000; 6(1):83–85.

    PubMed  CAS  Google Scholar 

  77. Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 2005; 162(2):361–369.

    PubMed  Google Scholar 

  78. 78.Taylor MJ, Schweinsburg BC, Alhassoon OM, Gongvatana A, Brown GG, Young-Casey Cet al. Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. J Neurovirol 2007; 13(2):150–159.

    PubMed  CAS  Google Scholar 

  79. Jernigan TL, Gamst AC, Archibald SL, Fennema-Notestine C, Mindt MR, Marcotte TD et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005; 162(8):1461–1472.

    PubMed  Google Scholar 

  80. Bartok JA, Martin EM, Pitrak DL, Novak RM, Pursell KJ, Mullane KM et al. Working memory deficits in HIV-seropositive drug users. J Int Neuropsychol Soc 1997; 3(5):451–456.

    PubMed  CAS  Google Scholar 

  81. Farinpour R, Martin EM, Seidenberg M, Pitrak DL, Pursell KJ, Mullane KM et al. Verbal working memory in HIV-seropositive drug users. J Int Neuropsychol Soc 2000; 6(5):548–555.

    PubMed  CAS  Google Scholar 

  82. Martin EM, Sullivan TS, Reed RA, Fletcher TA, Pitrak DL, Weddington W et al. Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc 2001; 7(1):20–26.

    PubMed  CAS  Google Scholar 

  83. Martin EM, Pitrak DL, Rains N, Grbesic S, Pursell K, Nunnally G et al. Delayed nonmatch-to-sample performance in HIV-seropositive and HIV-seronegative polydrug abusers. Neuropsychology 2003; 17(2):283–288.

    PubMed  Google Scholar 

  84. Martin EM, Pitrak DL, Weddington W, Rains NA, Nunnally G, Nixon H et al. Cognitive impulsivity and HIV serostatus in substance dependent males. J Int Neuropsychol Soc 2004; 10(7):931–938.

    PubMed  Google Scholar 

  85. Concha M, Graham NM, Munoz A, Vlahov D, Royal W, III, Updike M et al. Effect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity. Am J Epidemiol 1992; 136(11):1338–1348.

    PubMed  CAS  Google Scholar 

  86. Concha M, Selnes OA, Vlahov D, Nance-Sproson T, Updike M, Royal W et al. Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men. Neuroepidemiology 1997; 16(2):78–85.

    PubMed  CAS  Google Scholar 

  87. Selnes OA, McArthur JC, Royal W, III, Updike ML, Nance-Sproson T, Concha M et al. HIV-1 infection and intravenous drug use: longitudinal neuropsychological evaluation of asymptomatic subjects. Neurology 1992; 42(10):1924–1930.

    PubMed  CAS  Google Scholar 

  88. Bornstein RA, Fama R, Rosenberger P, Whitacre CC, Para MF, Nasrallah HA et al. Drug and alcohol use and neuropsychological performance in asymptomatic HIV infection. J Neuropsychiatry Clin Neurosci 1993; 5(3):254–259.

    PubMed  CAS  Google Scholar 

  89. Cristiani SA, Pukay-Martin ND, Bornstein RA. Marijuana use and cognitive function in HIV-infected people. J Neuropsychiatry Clin Neurosci 2004; 16(3):330–335.

    PubMed  Google Scholar 

  90. Basso MR, Bornstein RA. Neurobehavioural consequences of substance abuse and HIV infection. J Psychopharmacol 2000; 14(3):228–237.

    PubMed  CAS  Google Scholar 

  91. Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry 2004; 161(2):249–254.

    PubMed  Google Scholar 

  92. Schulte T, Mueller-Oehring EM, Rosenbloom MJ, Pfefferbaum A, Sullivan EV. Differential effect of HIV infection and alcoholism on conflict processing, attentional allocation, and perceptual load: evidence from a Stroop Match-to-Sample task. Biol Psychiatry 2005; 57(1):67–75.

    PubMed  Google Scholar 

  93. Rothlind JC, Greenfield TM, Bruce AV, Meyerhoff DJ, Flenniken DL, Lindgren JA et al. Heavy alcohol consumption in individuals with HIV infection: effects on neuropsychological performance. J Int Neuropsychol Soc 2005; 11(1):70–83.

    PubMed  Google Scholar 

  94. Durvasula RS, Myers HF, Mason K, Hinkin C. Relationship between alcohol use/abuse, HIV infection and neuropsychological performance in African American men. J Clin Exp Neuropsychol 2006; 28(3):383–404.

    PubMed  Google Scholar 

  95. Durvasula RS, Myers HF, Satz P, Miller EN, Morgenstern H, Richardson MA et al. HIV-1, cocaine, and neuropsychological performance in African American men. J Int Neuropsychol Soc 2000; 6(3):322–335.

    PubMed  CAS  Google Scholar 

  96. Basso MR, Bornstein RA. Effects of past noninjection drug abuse upon executive function and working memory in HIV infection. J Clin Exp Neuropsychol 2003; 25(7):893–903.

    PubMed  Google Scholar 

  97. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 2004; 10(1):1–14.

    PubMed  CAS  Google Scholar 

  98. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Heaton RK, Grant I. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav 2006; 10(2):185–190.

    PubMed  Google Scholar 

  99. Benhamou Y, Bochet M, Di M, V, Charlotte F, Azria F, Coutellier A et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30(4):1054–1058.

    CAS  Google Scholar 

  100. Kramer JR, Giordano TP, Souchek J, El-Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005; 42(3):309–314.

    PubMed  Google Scholar 

  101. Laskus T, Radkowski M, Jablonska J, Kibler K, Wilkinson J, Adair D et al. Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood 2004; 103(10):3854–3859.

    PubMed  CAS  Google Scholar 

  102. Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC, Rakela J. Emerging evidence of hepatitis C virus neuroinvasion. AIDS 2005; 19(Suppl 3):S140–S144.

    PubMed  Google Scholar 

  103. Laskus T, Operskalski EA, Radkowski M, Wilkinson J, Mack WJ, deGiacomo M et al. Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis 2007; 195(1):124–133.

    PubMed  CAS  Google Scholar 

  104. Cribier B, Schmitt C, Bingen A, Kirn A, Keller F. In vitro infection of peripheral blood mononuclear cells by hepatitis C virus. J Gen Virol 1995; 76(10):2485–2491.

    PubMed  CAS  Google Scholar 

  105. Sansonno D, Iacobelli AR, Cornacchiulo V, Iodice G, Dammacco F. Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. Clin Exp Immunol 1996; 103(3):414–421.

    PubMed  CAS  Google Scholar 

  106. Flugel A, Bradl M, Kreutzberg GW, Graeber MB. Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J Neurosci Res 2001; 66(1):74–82.

    PubMed  CAS  Google Scholar 

  107. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35(2):440–446.

    PubMed  Google Scholar 

  108. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9(6):847–854.

    PubMed  Google Scholar 

  109. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41(4):801–808.

    PubMed  Google Scholar 

  110. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition–the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002; 50(12):2041–2056.

    PubMed  Google Scholar 

  111. Rostasy K, Monti L, Lipton SA, Hedreen JC, Gonzalez RG, Navia BA. HIV leucoencephalopathy and TNFalpha expression in neurones. J Neurol Neurosurg Psychiatry 2005; 76(7):960–964.

    PubMed  CAS  Google Scholar 

  112. Paul R, Letendre S, Dearborne J. Cognitive function in patients co-infected with hepatitis C and human immunodeficiency virus. Current Hepatitis Reports. In press.

    Google Scholar 

  113. Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002; 37(3):349–354.

    PubMed  Google Scholar 

  114. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358(9275):38–39.

    PubMed  CAS  Google Scholar 

  115. Forton DM, Taylor-Robinson SD, Thomas HC. Reduced quality of life in hepatitis C–is it all in the head? J Hepatol 2002; 36(3):435–438.

    PubMed  Google Scholar 

  116. Morgello S, Estanislao L, Ryan E, Gerits P, Simpson D, Verma S et al. Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. AIDS 2005; 19(Suppl 3):S116–S122.

    PubMed  Google Scholar 

  117. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62(6):957–962.

    PubMed  CAS  Google Scholar 

  118. Parsons TD, Tucker KA, Hall CD, Robertson WT, Eron JJ, Fried MW et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 2006; 20(12):1591–1595.

    PubMed  Google Scholar 

  119. Martin EM, Novak RM, Fendrich M, Vassileva J, Gonzalez R, Grbesic S et al. Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc 2004; 10(2):298–300.

    PubMed  Google Scholar 

  120. Richardson JL, Nowicki M, Danley K, Martin EM, Cohen MH, Gonzalez R et al. Neuropsychological functioning in a cohort of HIV – and hepatitis C virus-infected women. AIDS 2005; 19(15):1659–1667.

    PubMed  Google Scholar 

  121. von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, Kucukkoylu S, Koller H, Haslinger BA et al. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr 2004; 35(2):131–137.

    PubMed  Google Scholar 

  122. Thein H, Maruff P, Krahn M, Kaldor J, Koorey D, Brew B et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med 2007; 8(8):520–528.

    PubMed  CAS  Google Scholar 

  123. Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64(8):1343–1347.

    PubMed  CAS  Google Scholar 

  124. Letendre SL, Cherner M, Ellis RJ, Marquie-Beck J, Gragg B, Marcotte T et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005; 19(Suppl 3):S72–S78.

    PubMed  CAS  Google Scholar 

  125. van Gorp WG, Hinkin CH. Triple trouble: cognitive deficits from hepatitis C, HIV, and methamphetamine. Neurology 2005; 64(8):1328–1329.

    PubMed  Google Scholar 

  126. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 2003; 9(2):93–110.

    PubMed  Google Scholar 

  127. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000; 152(4):383–389.

    PubMed  CAS  Google Scholar 

  128. Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 2005; 46(1):79–87.

    PubMed  CAS  Google Scholar 

  129. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352(9142):1751–1752.

    PubMed  CAS  Google Scholar 

  130. Sherman KE, Shire NJ, Rouster SD, Peters MG, James KM, Chung RT et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128(2):313–327.

    PubMed  CAS  Google Scholar 

  131. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123(4):1061–1069.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA

    Raul Gonzalez, Phillip J. Quartana & Eileen M. Martin

Authors
  1. Raul Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phillip J. Quartana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eileen M. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raul Gonzalez .

Editor information

Editors and Affiliations

  1. Department of Psychology Behavioral Neuroscience, University of Missouri – St. Louis, St. Louis, U.S.A.

    Robert H. Paul PhD

  2. Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.

    Ned Charlton Sacktor

  3. Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, U.S.A.

    Victor Valcour

  4. Memory and Aging Center Department of Neurology, UCSF, San Francisco, CA, U.S.A.

    Victor Valcour

  5. The Miriam Hospital, Alpert Medical School of Brown University, Providence, RI, U.S.A.

    Karen Tokie Tashima

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gonzalez, R., Quartana, P.J., Martin, E.M. (2009). Co-Occurrence of HIV, Hepatitis C, and Substance Use Disorders: Effects on Brain Functioning. In: Paul, R., Sacktor, N., Valcour, V., Tashima, K. (eds) HIV and the Brain. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59745-434-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-434-6_10

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-934115-08-4

  • Online ISBN: 978-1-59745-434-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation